FDA Grants Priority Review to Zanubrutinib as Therapy for Pretreated Marginal Zone Lymphoma
Dec 19, 2023
A supplemental new drug application for zanubrutinib (Brukinsa) as therapy for patients with marginal zone lymphoma (MZL) who have received 1 or more prior anti-CD20–based therapies was accepted and granted priority review by the FDA, according to the company responsible for developing the agent, Beigene, Ltd.1 The data supporting the filing come from the single-arm, open-label, multicenter, phase 2 MAGNOLIA trial (NCT03846427), which is examining the agent in patients with relapsed/refractory (R/R) MZL and is supported further by a global phase 1/2 trial (NCT02343120) in patients with B-cell malignancies. “This is our first regulatory submission in MZL, a serious disease diagnosed in more than 2000 patients every year in the US, with no clear standard of care. In clinical trials, Brukinsa has demonstrated promising efficacy and tolerability in MZL and presents a potential new option for MZL,” Jane Huang, MD, Chief Medical Officer of Hematology at BeiGene, said in a press release. “We look forward to continuing our communications with the FDA in the coming months as we work on advancing the broad global development program for our potentially best-in-class BTK inhibitor.”
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…